ChromaTan and Landmark Bio Awarded National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) Grant to Advance Intensified Recombinant Adeno-Associated Virus (AAV) Production Process
Grant allows ChromaTan and Landmark Bio to create a scalable, cost-effective, and accessible platform for the manufacturing and characterization of AAV-based gene therapy vectors


